Adc Therapeutics Sa Stock Price, News & Analysis

ADC Therapeutics (NYSE: ADCT) will present at three investor conferences in November 2025 with CEO Ameet Mallik participating in each session.

Schedule:

• Stephens Biotechnology Virtual Fireside Chats – Nov 3, 2025 at 12:00 p.m. ET (virtual; no replay or transcript)
• Guggenheim Second Annual Healthcare Innovation Conference – Nov 11, 2025 at 1:30 p.m. ET (Boston; live webcast available)
• Jefferies Global Healthcare Conference – Nov 19, 2025 at 12:30 p.m. GMT (London; live webcast available)

Live webcasts for Guggenheim and Jefferies will be available on the company’s Events & Presentations page at ir.adctherapeutics.com, and replays will be available for approximately 30 days after each event.

ADC Therapeutics (NYSE: ADCT) announced a $60.0 million PIPE financing on October 13, 2025, selling 11.3 million common shares at $4.00 each and pre-funded warrants to purchase 3.8 million shares at $3.90 each.

The PIPE is led by TCGX with participation from Redmile Group and others and is expected to close on October 27, 2025, subject to customary conditions. Net proceeds are estimated at $57.6 million after fees. The company reported Q3 2025 ZYNLONTA net product revenues of $15.8 million and $234.7 million cash on hand as of September 30, 2025, which would rise to approximately $292.3 million after the PIPE.

ADC Therapeutics (NYSE: ADCT) announced a $60.0 million PIPE financing on October 13, 2025, selling 11.3 million common shares at $4.00 each and pre-funded warrants to purchase 3.8 million shares at $3.90 each.

The PIPE is led by TCGX with participation from Redmile Group and others and is expected to close on October 27, 2025, subject to customary conditions. Net proceeds are estimated at $57.6 million after fees. The company reported Q3 2025 ZYNLONTA net product revenues of $15.8 million and $234.7 million cash on hand as of September 30, 2025, which would rise to approximately $292.3 million after the PIPE.

ADC Therapeutics (NYSE: ADCT) has granted stock options to four new employees as part of their employment inducement package. The grants, totaling options to purchase 162,000 common shares, were approved by the Company's Compensation Committee under the Inducement Plan.

The stock options will vest over a four-year period, with 25% vesting on the first anniversary and the remaining vesting monthly at 1/48th of the total shares, contingent on continued employment. The grants were made in compliance with NYSE's Listed Company Manual Rule 303A.08.

ADC Therapeutics (NYSE: ADCT) has announced equity compensation grants to two new employees as part of its employee inducement plan. The company granted options to purchase 29,700 common shares on September 2, 2025.

The grants were approved by the Compensation Committee under the Company's Inducement Plan and comply with NYSE's Listed Company Manual Rule 303A.08. The options will vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly thereafter, contingent on continued employment.

ADC Therapeutics (NYSE:ADCT), a commercial-stage leader in antibody drug conjugates (ADCs), announced its upcoming participation in the Cantor Global Healthcare Conference 2025. CEO Ameet Mallik will engage in a fireside chat on September 3, 2025, at 9:10 a.m. ET.

Investors can access the presentation through a webcast on the Events & Presentations page of ADC Therapeutics' investor relations website. The webcast recording will remain available for approximately 30 days after the event.

ADC Therapeutics (NYSE:ADCT) reported Q2 2025 financial results and operational updates, highlighting significant progress in their ZYNLONTA® clinical programs. The company's LOTIS-7 trial showed impressive results with 93.3% overall response rate and 86.7% complete response rate in combination with glofitamab for r/r DLBCL patients.

Key financial developments include a $100 million PIPE financing, extending cash runway into 2028, and Q2 2025 net product revenues of $18.1 million. The company reported a net loss of $56.6 million ($0.50 per share). A strategic restructuring plan was announced, reducing global workforce by 30% and discontinuing early development efforts in solid tumors to focus on ZYNLONTA.

The LOTIS-5 Phase 3 trial is expected to reach PFS events by end-2025, with potential sBLA submission in H1 2026. The company's cash position stands at $264.6 million as of June 30, 2025.

ADC Therapeutics (NYSE: ADCT), a commercial-stage leader in antibody drug conjugates, will host its Q2 2025 financial results conference call on August 12, 2025, at 8:30 a.m. EDT. The company will present financial results and provide business updates during the call.

Investors can access the conference via toll-free dial-in at 1-800-836-8184 for North America and Canada. A live webcast will be available on the company's investor relations website, with the recording accessible for 30 days after the event.

ADC Therapeutics (NYSE: ADCT), a commercial-stage leader in antibody drug conjugates, has granted stock options for 127,000 common shares to three new employees as employment inducement awards. The grants were approved by the Company's Compensation Committee under the Inducement Plan.

The options will vest over a four-year period, with 25% vesting on the first anniversary and the remaining vesting monthly thereafter, contingent on continued employment. These grants were made under NYSE's Listed Company Manual Rule 303A.08 employment inducement exemption.